Abametapir and Saquinavir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jun 30, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abametapir
No brand names on recordSaquinavir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Abametapir is a lotion used to treat head lice. Even though you put it on your scalp, a little gets into your body and can briefly slow down a liver enzyme (called CYP3A4) that breaks down many other medicines. Saquinavir is an HIV medicine cleared by that same enzyme.
When the enzyme is slowed, saquinavir can build up in your blood and cause stronger effects or more side effects. This is based on how the drugs are expected to behave, not on real-world reports, but the concern is taken seriously. The good news: your care team can manage this easily, often by spacing the two apart. Please talk with your pharmacist or doctor before using both.
Mechanism: Abametapir is a CYP3A4 inhibitor. Saquinavir is a CYP3A4 substrate, so co-administration is predicted to reduce saquinavir metabolism and increase its systemic exposure (AUC/Cmax), with rapid onset. Neither agent's activation is compromised (saquinavir's effect is driven by parent drug), so the net effect is potentiation of saquinavir exposure and toxicity risk.
- Direction: increased saquinavir exposure and effect
- Evidence: theoretical
- Severity: major
- Management: Avoid CYP3A4 substrates for 2 weeks after abametapir application; if unavoidable, avoid abametapir. Consider closer clinical monitoring if concurrent use cannot be prevented.
What happens
Increased exposure of CYP3A4 substrate
Interaction Deep Dive
For a period of 2 weeks following the application of abametapir, refrain from using CYP3A4 substrates. Should avoiding these substrates not be possible, then abametapir itself should be avoided1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism by abametapir
How to manage this interaction
What your care team may do:
- Separate the two treatments in time. Guidance is to avoid CYP3A4 substrates such as saquinavir for 2 weeks after applying abametapir.
- If that timing is not workable, the alternative is to avoid the abametapir treatment and choose another lice option.
- If both must be used, your team may monitor you more closely for stronger saquinavir effects.
What you should do: Keep taking your prescribed HIV medicine and do not stop anything on your own. Before using an abametapir lice product, tell your pharmacist or prescriber you take saquinavir so they can help you time it safely.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abametapir and Saquinavir together?
Abametapir can raise saquinavir levels by briefly blocking the enzyme that clears it, so avoid saquinavir (and other CYP3A4 drugs) for 2 weeks after using abametapir, or skip the abametapir. Check with your pharmacist or doctor before combining them. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abametapir and Saquinavir interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How is the Abametapir and Saquinavir interaction managed?
What your care team may do: Separate the two treatments in time. Guidance is to avoid CYP3A4 substrates such as saquinavir for 2 weeks after applying abametapir. If that timing is not workable, the alternative is to avoid the abametapir treatment and choose another lice option. If both must be used, your team may monitor you more closely for stronger saquinavir effects. What you should do: Keep ta… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abametapir or Saquinavir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XEGLYZE(TM) topical lotion, abametapir topical lotion. Dr Reddy’s Laboratories Inc (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Abametapir
Keep reading about Saquinavir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist